This latest approval now makes enzalutamide the only FDA-approved oral medication indicated for both metastatic and nonmetastatic castration-resistant prostate cancer.
Pulmonary embolism is associated with GnRH agonist use and orchiectomy.
The impact of partial brachytherapy on metastasis and disease-specific mortality is unclear.
Incidence of tx-emergent small-cell neuroendocrine prostate cancer 17% among those with mCRPC.
Failure-free survival was 88% at 5 years among patients with nonmetastatic prostate cancer who underwent focal therapy with high-intensity focused ultrasound.
aBSI validated as prognostic biomarker of survival in metastatic castration-resistant prostate cancer
More conservative management and active surveillance utilized at VA hospitals from 2005 to 2015.
Metformin plus androgen deprivation therapy is associated with a lower death risk vs ADT alone in men without diabetes, study of US veterans shows.
Men receiving enzalutamide plus ADT had a significant 71% lower risk for metastasis or death compared with men receiving placebo plus ADT.
Children who migrated to the UK from Bangladesh before puberty and Bangladeshis born in the UK had significantly higher levels of testosterone compared with life-long residents of Bangladesh.
In a phase 3 trial, Prostvac-V/F did not significantly prolong overall survival among men with asymptomatic or minimally symptomatic mCRPC.
Researchers question the generalizability of a major study showing no significant difference in cancer-specific and overall survival between surgery and observation for localized prostate cancer.
Men with advanced prostate cancer at diagnosis have an elevated risk of spinal cord compression, renal failure, and other cancer-related morbidities.
Study participants with acute urinary retention after TRUS-guided prostate biopsy were 4.5 times more likely to skip a recommended re-biopsy than men who had no initial biopsy-related complications.
Clinicians can rest easier about recommending finasteride to more men, according to experts.
Those with worse emotional distress also report worse urinary, sexual, bowel functions.
If externally validated, bpMRI could be used to triage men for prostate biopsy.
Abiraterone plus prednisone was associated with significantly greater PSA progression-free survival among patients who are black compared with white patients.
In 2015, 69% of surgeries for prostate, bladder, and kidney cancer were performed with robotic assistance, a new meta-analysis shows.
Enzalutamide decreases the risk of clinically meaningful deterioration in HRQoL compared with placebo in men with non-metastatic CRPC, new study finds.
"We are confident this guideline is fully aligned with the latest science on treatments for patients with non-metastatic and metastatic CRPC," said Michael Cookson, MD, member of the 2018 amendment panel.
Findings for men with intermediate- and high-risk prostate cancer.
In a meta-analysis, smokers had an 89% greater risk of dying from prostate cancer compared with nonsmokers.
The approval of Yonsa was based on 2 randomized, placebo-controlled, multicenter Phase 3 studies in patients with mCRPC.
Sharpest decrease seen in privately insured men after 2011.
Men with low-risk PCa who underwent partial gland ablation with vascular-targeted photodynamic therapy were less likely than those on AS to require radical treatment.
The percentage of prostate cancer patients with positive lymph nodes increased from 2.4% in 2010 to 4.7% in 2014.
Men with Peyronie's disease have elevated risks of benign prostatic hyperplasia, prostatitis, and testis and prostate cancer, new studies reveal.
Findings from the largest study to date examining the effect of TRT in prostate cancer patients build on previous evidence showing that the treatment does not affect disease progression risk.
At 1 year post-op, patients with MetS prior to prostate surgery had a significantly lower continence rate than those without MetS (75.4% vs 82.6%).
Renal and Urology News Articles
- Medication Adherence Low in Gout Patients Initiating Allopurinol
- Trials Supporting FDA Approval of Breakthrough Drugs Examined
- FDA Approves Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer
- Urine Cytology May Not Improve Hematuria Evaluation for Bladder Cancer
- Bladder Hydrodistention May Ease Nocturia in Interstitial Cystitis
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)